

<sup>3</sup><sub>29</sub>  
40. A method in accordance with claim <sup>28</sup><sub>29</sub>, wherein the autoimmune disease comprises multiple sclerosis, graft vs. host disease, psoriasis, juvenile onset diabetes, Sjogrens' disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.

<sup>4</sup><sub>30</sub>  
41. A method in accordance with claim <sup>27</sup><sub>30</sub>, wherein the T-cell mediated disorder comprises severe vasculitis, rheumatoid arthritis or systemic lupus.

<sup>5</sup><sub>31</sub>  
42. A method in accordance with claim <sup>30</sup><sub>41</sub>, wherein the T-cell mediated disorder is rheumatoid arthritis.

<sup>6</sup><sub>32</sub>  
43. A method in accordance with claim <sup>27</sup><sub>38</sub> or <sup>28</sup><sub>39</sub>, wherein the antibody is an anti-CDw52 antibody.

<sup>7</sup><sub>33</sub>  
44. A method in accordance with claim <sup>27</sup><sub>38</sub> or <sup>28</sup><sub>39</sub>, wherein the antibody is an anti-CD4 antibody.

<sup>34</sup>  
45. A method in accordance with claim <sup>27</sup><sub>38</sub> or <sup>28</sup><sub>39</sub>, wherein the altered antibody is a chimeric or CDR-grafted antibody.--

#### REMARKS

No new matter is introduced into this application by the introduction of the new claims set forth above. Support for new claim 38 can be found on page 10 of the specification and, for example, in claim 19 of the parent application. Support for claims 39-42 also can be found on page 10 of the specification. Support for claim 43 can be found in example 5 and in the paragraph bridging pages 5 and 6. Support for claims 44 and 45 can be found in this same paragraph.